ePrivacy and GPDR Cookie Consent by TermsFeed Generator
Go From Sample to Library with Special Pricing on Genome Assembly Services | Through March 1, 2024 | |Learn More


Carlsbad, Calif. (November 1, 2022) Arima Genomics, Inc.,  today announced that new data on the detection of actionable fusion-based biomarkers in formalin-fixed, paraffin-embedded (FFPE) specimens from patients with various cancer indications will be presented at the Association of Molecular Pathology Annual Meeting and Expo in Phoenix, Ariz. The data, developed in partnership with researchers from NYU Langone Health, shows how Arima Genomics’ technology was useful in detecting previously undetected actionable gene fusions, meaning that those variants were the target of on-market therapies, or the target of therapies investigated in ongoing clinical trials, or of diagnostic or prognostic value impacting treatment plans.

Arima Genomics’ technology maps the 3-dimensional structure of chromosomes within the nucleus of a cell, enabling researchers to amplify and locate gene fusions.

“Current methods for sequencing FFPE tumor tissues often fail to identify genomic alterations such as gene fusions responsible for driving disease,” said Matija Snuderl, MD, Director of Molecular Pathology and Diagnostics at NYU Grossman School of Medicine. “In our study of >100 samples, Arima’s 3D genomics-based approach consistently detected gene fusions identified by other methods such as RNA sequencing, and where those methods did not find a driver of the patient’s cancer, the Arima assay detected clinically actionable alterations in 53% of the cases. Our work shows the promise of Arima’s technology in increasing the diagnostic yield across cancers and its potential role in improving patient outcomes by identifying more patients eligible for targeted therapies.”

“Our research-based efforts to understand the utility of 3D genomics in pan-cancer profiling have demonstrated strong potential for this technology,” said Anthony Schmitt, PhD, Senior Vice President of Science, Arima Genomics. “Our technology was able to identify structural variants of clinical significance both in archival FFPE tissue samples for which other technologies, such as RNA-seq, are unsuccessful and in driver-negative clinical samples. As a result, we believe Arima’s 3D genomic approach can be broadly deployed for translational medicine research and clinical testing.”

Arima Genomics will host a workshop with Drs. Anthony Schmitt and Matija Snuderl, on November 2, 2022, at 2:00 p.m. in Room 231C. In addition, a poster titled “Uncovering gene fusions with 3D genomics: from clinical validation to actionable insights for undiagnosable solid tumors,” will be presented on Saturday, November 5, 2022, at 9:15-10:15 a.m. by Dr. Kristyn Galbraith of NYU.

For more information, visit Arima Genomics at booth #1539 or https://arimagenomics.com/amp-2022/

About Arima Genomics

Arima Genomics, Inc. is advancing life sciences research through the power of 3D genomics by providing unparalleled access to the sequence and structure of any genome. Arima Genomics offers the most advanced technologies for preserving the structural organization of the genome to drive discovery in genome biology and human health. To learn more, visit www.arimagenomics.com and connect with us on Twitter, LinkedIn, and YouTube.


Gwen Gordon

General inquiries
Pamela Bentley Mills, PhD


Originally published by BusinessWire